Apoptosis induction by (+)α-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells

Leukemia Research

Volumn 33, Issue 7, 2009, Pages 958-963

  Freitas, Rosana Aparecida ^a   Silva dos Santos, Guilherme Augusto ^a   Gimenes Teixeira, Hamilton Luiz ^a   Scheucher, Priscila Santos ^a   Lucena Araujo, Antonio Roberto ^a   Lima, Ana Sílvia Gouveia ^a   Abreu e Lima, Rodrigo Siqueira ^a   Garcia, Aglair Bergamo ^a   Jordão Jr , Alceu Afonso ^a   Falcão, Roberto Passetto ^a   Vannucchi, Hélio ^a   Rego, Eduardo Magalhães ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

tocopheryl succinate; Acute promyelocytic leukemia; Apoptosis; Arsenic trioxide

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; ARSENIC TRIOXIDE; CD34 ANTIBODY; METHYLCELLULOSE; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL ASSAY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LIPID PEROXIDATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ALPHA-TOCOPHEROL; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; ARSENICALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; GROWTH INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIPID PEROXIDATION; OXIDES; TRETINOIN;

EID: 67349155010     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.035     Document Type: Article

References (33)

1. Sanz M.A., Martin G., Gonzalez M., Leon A., Rayon C., Rivas C., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103 (2004) 1237-1243
2. Gallagher R.E. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 16 (2002) 1940-1958
3. Mathews V., George B., Lakshmi K.M., Viswabandya A., Bajel A., Balasubramanian P., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107 (2006) 2627-2632
4. Thomas X., Pigneux A., Raffoux E., Huguet F., Caillot D., and Fenaux P. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia. Haematologica 91 (2006) 996-997
5. Wang G., Li W., Cui J., Gao S., Yao C., Jiang Z., et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 22 (2004) 63-71
6. Aribi A., Kantarjian H.M., Estey E.H., Koller C.A., Thomas D.A., Komblau S.M., et al. Combination therapy with arsenic trioxide, all-trans-retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109 (2007) 1355-1359
7. Quezada G., Koop L., Estey E., and Wells R.J. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Pediatr Blood Cancer 51 (2008) 133-135
8. Ribeiro R.C., and Rego E.M. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology 1 (2006) 162-168 [ASH Educational Program Book]
9. Cyranoski D. Arsenic patent keeps drug for rare cancer out of reach of many. Nat Med 13 (2007) 1005
10. Mathews V., Desire S., George B., Lakshmi K.M., Rao J.G., Viswabandya A., et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia 20 (2006) 881-883
11. Naito K., Kobayashi M., Sahara N., Shigeno K., Nakamura S., Shinjo K., et al. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy. Int J Hematol 83 (2006) 318-323
12. Turley J.M., Fu T., Ruscetti F.W., Mikovits J.A., Bertolette III D.C., and Birchenall-Roberts M.C. Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res 57 (1997) 881-890
13. Crispen P.L., Uzzo R.G., Golovine K., Makhov P., Pollack A., Horwitz E.M., et al. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate 67 (2007) 582-590
14. Basu A., Grossie B., Bennett M., Mills N., and Imrhan V. Alpha-tocopheryl succinate (alpha-TOS) modulates human prostate LNCaP xenograft growth and gene expression in BALB/c nude mice fed two levels of dietary soybean oil. Eur J Nutr 46 (2007) 34-43
15. Malafa M.P., Fokum F.D., Mowlavi A., Abusief M., and King M. Vitamin E inhibits melanoma growth in mice. Surgery 131 (2002) 85-91
16. Quin J., Engle D., Litwiller A., Peralta E., Grasch A., Boley T., et al. Vitamin E succinate decreases lung cancer tumor growth in mice. J Surg Res 127 (2005) 139-143
17. Bang O.S., Park J.H., and Kang S.S. Activation of PKC but not of ERK is required for vitamin E-succinate-induced apoptosis of HL-60 cells. Biochem Biophys Res Commun 288 (2001) 789-797
18. Yamamoto S., Tamai H., Ishisaka R., Kanno T., Arita K., Kobuchi H., et al. Mechanism of alpha-tocopheryl succinate-induced apoptosis of promyelocytic leukemia cells. Free Radic Res 33 (2000) 407-418
19. Volpi E.V., Vatchva R., Labella T., and Gan S.U. More detailed characterization of some of the HL-60 karyotypic features by fluorescence in situ hybridization. Cancer Genet Cytogenet 87 (1996) 103-106
20. Rego E.M., and Pandolfi P.P. Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Semin Hematol 38 (2001) 54-70
21. Neuzil J., Tomasetti M., Zhao Y., Dong L.F., Birringer M., Wang X.F., et al. Vitamin E analogs, a novel group of "mitocans," as anticancer agents: the importance of being redox-silent. Mol Pharmacol 71 (2007) 1185-1199
22. Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., and Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77 (1991) 1080-1086
23. Chou T.C. Theoretical basis, experimental design and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58 (2006) 621-681
24. van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 13 (1999) 1901-1928
25. Buege J.A., and Aust S.D. Microsomal lipid peroxidation. Methods Enzymol 52 (1978) 302-310
26. Arnaud J., Fortis I., Blachier S., Kia D., and Favier A. Simultaneous determination of retinol, alpha-tocopherol and beta-carotene in serum by isocratic high-performance liquid chromatography. J Chromatogr 572 (1991) 103-116
27. Kitareewan S., Roebuck B.D., Demidenko E., Sloboda R.D., and Dmitrovsky E. Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst 99 (2007) 41-52
28. Weber T., Lu M., Andera L., Lahn H., Gellert N., Fariss M., et al. Vitamin A succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clin Cancer Res 8 (2002) 863-869
29. Karasavvas N., Carcamo J.M., Stratis G., and Golde D.W. Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 105 (2005) 4004-4012
30. Davison K., Côte S., Mader S., and Miller Jr. W.H. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17 (2003) 931-940
31. Diaz Z., Colombo M., Mann K.K., Su H., Smith K.N., Bohle D.S., et al. Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood 105 (2005) 1237-1245
32. Milella M., Kornblau S.M., Estrov Z., Carter B.Z., Lapillonne H., Harris D., et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108 (2001) 851-859
33. Estey E., Garcia-Manero G., Ferrajoli A., Faderl S., Vertovsek S., Jones D., et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute Promyelocytic leukemia. Blood 107 (2006) 3469-3473